NCT01751763

Sorafenib for Residue Disease After Resection With Curative Intent

Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 106 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Radical hepatic resection represents one of the treatment options offering a prospect for cure with 5-year survival rates up to 50%. However, unintentionally, quite a proportion of these "radical resection" actually turned out to be non-radical in nature. For these patients who actually received non-radical resection, their by year survival rates were much lower than those who received radical hepatectomy. In this prospective, non-interventional, multi-center study, we are planning to observe the patient characteristics of Hepatocellular carcinoma (HCC) patients who have residual disease after resection with curative intent, as well as treatment pattern, safety and effectiveness of sorafenib for these patients.

Conditions

• Carcinoma, Hepatocellular

Interventions

Type	Name	Description
DRUG	Sorafenib (Nexavar, BAY43-9006)	treatment (including dose, duration, modification) decided by the investigator.

Timeline

• Start date: 2013-07-09
• Primary completion: 2016-12-31
• Completion: 2017-09-08
• First posted: 2012-12-18
• Last updated: 2017-09-25

Locations

1 site across 1 country: China